<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Previous studies have shown that serum levels of deoxythymidine kinase (sTK) provide useful prognostic information in various <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, such as <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Using a radioenzyme assay, the authors determined sTK in 146 patients with primary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Morphologic subtypes were <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) in 18 patients, RA with ring sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) in 24, RA with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) in 41, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/T) in 29, and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) in 34 </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Enzyme levels ranged from 1.1 to 829 U/microliters </plain></SENT>
<SENT sid="4" pm="."><plain>One hundred fifteen (79%) patients had elevated sTK levels (more than 5 U/microliters) at the time of diagnosis </plain></SENT>
<SENT sid="5" pm="."><plain>In advanced stages of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/T) enzyme activities were higher than in early stages (RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>However, sTK levels were not correlated with the percentage of medullary blast cells </plain></SENT>
<SENT sid="7" pm="."><plain>Among other parameters tested, the best correlation with sTK was found for serum <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (LDH) activity (r = 0.29; P &lt; 0.0005) </plain></SENT>
<SENT sid="8" pm="."><plain>As shown by life table analysis, sTK activity at diagnosis provided useful information regarding the prognosis of patients </plain></SENT>
<SENT sid="9" pm="."><plain>For patients with sTK levels of less than 10 U/microliters, actuarial survival after 2 years was 65%, compared with 33% for those with enzyme values of 10 U/microliters or greater </plain></SENT>
<SENT sid="10" pm="."><plain>The 5-year cumulative survival rates were 34% and 14%, respectively (P &lt; 0.0005) </plain></SENT>
<SENT sid="11" pm="."><plain>However, sTK levels at diagnosis were not useful for predicting transformation to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Nine of 61 (15%) patients with sTK of less than 10 U/microliters had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> develop, whereas 15 of 57 (26%) patients with sTK of 10 U/microliters or greater had disease progress to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (chi-square, 1.64; P = 0.2) </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Considering the lack of correlation with bone marrow blasts, the authors conclude that increased sTK levels in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are primarily attributable to intramedullary destruction of hematopoietic precursors and do not reflect the leukemic blast cell burden </plain></SENT>
<SENT sid="14" pm="."><plain>This appears similar to the ineffective hematopoiesis of <z:hpo ids='HP_0100502'>vitamin B12 deficiency</z:hpo>, which is associated with elevated levels of sTK and LDH </plain></SENT>
<SENT sid="15" pm="."><plain>The data suggest that sTK is a prognostic parameter that can be used to predict the survival of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>However, multivariate analysis shows that the predictive value of sTK is not superior to that of LDH </plain></SENT>
</text></document>